Review and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Disease
The DOI matches its Crossref record.
Abstract
Mild Alzheimer's disease (AD) is often difficult to differentiate from mild cognitive impairment (MCI) or non-AD dementias. A multitude of diagnostic biomarkers and advanced imaging strategies have been developed to aid in the diagnosis and management of AD. We sought to review and analyze the published evidence on key test characteristics of major diagnostic strategies to formulate best estimates of sensitivity (SN) and specificity (SP). A systematic review was undertaken to locate and abstract all studies of biomarkers or diagnostic imaging for AD published in English from January 1990 to March 2010 that provided estimates of SN and SP. Meta-analysis was performed using a bivariate mixed-effects binary regression model. We calculated -SN, SP, and area under the receiver operating curves (AUROC), with confidence and prediction contours. Of 1,840 unique studies identified, 119 presented primary data sufficient for analysis. SN and SP were calculated against non-demented controls, non-AD dementias with and without MCI, if available. Compared to non-demented controls, FDG-PET demonstrated the highest AUROC (0.96), with 90% SN (95%CI 84% to 94%), and 89% SP (95% CI 81% to 94%). FDG-PET also was most accurate in discriminating AD from demented controls (including MCI) with AUROC 0.91, and 92% SN (95%CI 84% to 96%) and 78% SP (95% CI 69% to 85%). For discrimination of AD from non-AD dementias (excluding MCI), CSF Ptau, and SPECT produced identical AUROC (0.86). Diagnostic strategies for AD show wide variation in test characteristics and some show promise for use in clinical practice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Meta-analytic evidence suggests that FDG-PET has 90% sensitivity and 89% specificity in diagnosing AD from controls [109].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [109]
Citations
Cites
Still being checked.
Cited by
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
2013 Alzheimer's disease facts and figures
Alzheimer's Association, Thies, W., & Bleiler, L. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,328
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
2020 Alzheimer's disease facts and figures
(2020) · Alzheimer's & Dementia · doi:10.1002/alz.12068 · Cited by 2,353
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
2017 Alzheimer's disease facts and figures
(2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.001 · Cited by 1,311
2014 Alzheimer's disease facts and figures
Alzheimer's Association (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.001 · Cited by 1,020
A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using 18 F-FDG PET of the Brain
Ding, Y., Sohn, J. H., Kawczynski, M. G., Trivedi, H., Harnish, R., Jenkins, N. W., Lituiev, D., Copeland, T. P., Aboian, M. S., Mari Aparici, C., et al. (2019) · Radiology · doi:10.1148/radiol.2018180958 · Cited by 577
Plasma tau in Alzheimer disease
Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P. S., Andreasson, U., Stomrud, E., Palmqvist, S., Baker, D., Tan Hehir, C. A., Jeromin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003246 · Cited by 502
“Patients with a clinical syndrome of AD dementia met the DSM-III-R criteria for dementia19 and the National Institute of Neurologic and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria for AD.11 All participants with plasma tau data were included.”
BackgroundInfluentialBrain PET in the Diagnosis of Alzheimer’s Disease
Marcus, C., Mena, E., & Subramaniam, R. M. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000547 · Cited by 382
CSF biomarker variability in the Alzheimer's Association quality control program
Mattsson, N., Andreasson, U., Persson, S., Carrillo, M. C., Collins, S., Chalbot, S., Cutler, N., Dufour‐Rainfray, D., Fagan, A. M., Heegaard, N. H. H., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.010 · Cited by 382
Dukart, J., Holiga, S., Rullmann, M., Lanzenberger, R., Hawkins, P. C. T., Mehta, M. A., Hesse, S., Barthel, H., Sabri, O., Jech, R., et al. (2021) · Human Brain Mapping · doi:10.1002/hbm.25244 · Cited by 347
van Oostveen, W. M., & de Lange, E. C. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042110 · Cited by 297
Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease
Bader, J. M., Geyer, P. E., Müller, J. B., Strauss, M. T., Koch, M., Leypoldt, F., Koertvelyessy, P., Bittner, D., Schipke, C. G., Incesoy, E. I., et al. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199356 · Cited by 286
“There is no universally accepted AD classification system; however, various different integration schemes of clinical AD CSF biomarkers have been explored (Bloudek et al , 2011; Ferreira et al , 2014; Ritchie et al , 2017).”
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
Brain FDG PET and the Diagnosis of Dementia
Shivamurthy, V. K. N., Tahari, A. K., Marcus, C., & Subramaniam, R. M. (2015) · American Journal of Roentgenology · doi:10.2214/ajr.13.12363 · Cited by 227
“FDG PET also was more accurate in discriminating patients with AD from demented control subjects, including those with mild cognitive impairment (MCI), with 92% sensitivity (95% CI, 84–96%) and 78% specificity (95% CI, 69–85%) [24].”
BackgroundInfluentialThe use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 221
“Meta-analytic evidence suggests that FDG-PET has 90% sensitivity and 89% speci fi city in diagnosing AD from controls [109].”
BackgroundSPECT and PET imaging in Alzheimer’s disease
Valotassiou, V., Malamitsi, J., Papatriantafyllou, J., Dardiotis, E., Tsougos, I., Psimadas, D., Alexiou, S., Hadjigeorgiou, G., & Georgoulias, P. (2018) · Annals of Nuclear Medicine · doi:10.1007/s12149-018-1292-6 · Cited by 169
EFNS task force: the use of neuroimaging in the diagnosis of dementia
Filippi, M., Agosta, F., Barkhof, F., Dubois, B., Fox, N. C., Frisoni, G. B., Jack, C. R., Johannsen, P., Miller, B. L., Nestor, P. J., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03859.x · Cited by 141
Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia
Simonsen, A. H., Herukka, S.-K., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.09.008 · Cited by 138
The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients
Cistaro, A., Pagani, M., Montuschi, A., Calvo, A., Moglia, C., Canosa, A., Restagno, G., Brunetti, M., Traynor, B. J., Nobili, F., et al. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2667-5 · Cited by 129
“This is being progressively achieved in, for example, Alzheimer’s Disease and mild cognitive impairment, in which FDG PET investigations provide reliable discriminations between the two groups of patients as well as between patients and controls [18, 19].”
BackgroundGaugler, J. E., Ascher-Svanum, H., Roth, D. L., Fafowora, T., Siderowf, A., & Beach, T. G. (2013) · BMC Geriatrics · doi:10.1186/1471-2318-13-137 · Cited by 97
Fantoni, E. R., Chalkidou, A., O’ Brien, J. T., Farrar, G., & Hammers, A. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171093 · Cited by 68
“Similar analyses have been conducted on other relevant dementia tests, such as [18F]fluorodeoxyglucose PET (FDG) [18, 19], cerebrospinal fluid (CSF) analysis [18, 20], magnetic resonance imaging (MRI) [18], and Mini-Mental State Examination (MMSE) scoring [21].”
MethodClarke, N., Barrick, T. R., & Garrard, P. (2021) · Frontiers in Computer Science · doi:10.3389/fcomp.2021.634360 · Cited by 65
“All three approaches can distinguish AD from controls with accuracies of over 90% (Bloudek et al., 2011), but are less accurate for MCI (Mitchell, 2009; Lombardi et al., 2020).”
BackgroundRetinal examination for the diagnosis of Alzheimer's disease
Kayabasi, U. (2014) · International Journal of Ophthalmic & Pathology · doi:10.4172/2324-8599.1000145 · Cited by 34
Rogeau, A., Hives, F., Bordier, C., Lahousse, H., Roca, V., Lebouvier, T., Pasquier, F., Huglo, D., Semah, F., & Lopes, R. (2024) · NeuroImage · doi:10.1016/j.neuroimage.2024.120530 · Cited by 29
Metadata
- Authors
- Bloudek, L. M., Spackman, D. E., Blankenburg, M., & Sullivan, S. D.
- Affiliations
- Allergan, Inc., Irvine, CA, USA
- University of York, Centre for Health Economics, York, UK
- Bayer (Germany) (DE)
- University of Washington (US)
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2011-10-04
- Volume
- 26
- Issue
- 4
- Pages
- 627-645
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1829865020
- Cited by
- 282
- References
- 0
- Citations by year
- 2026: 12 · 2025: 12 · 2024: 18 · 2023: 8 · 2022: 24 · 2021: 29 · 2020: 27 · 2019: 20 · 2018: 18 · 2017: 21 · 2016: 21 · 2015: 17 · 2014: 28 · 2013: 15 · 2012: 11
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bayer HealthCare
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, diagnostic biomarkers
- MeSH terms
- Alzheimer Disease, Diagnosis, Differential, Humans, Image Processing, Computer-Assisted, Magnetic Resonance Imaging, Neuropsychological Tests, ROC Curve, Tomography, X-Ray Computed, Biomarkers, Tomography, Emission-Computed, Single-Photon, Amyloid beta-Peptides, tau Proteins, Area Under Curve, Positron-Emission Tomography, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.